![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 7
2017
Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E. und Fasching, P. A.
(2017):
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis.
In: Cancer Research, Bd. 77
2016
Schwentner, L.; Harbeck, N.; Singer, S.; Eichler, M.; Rack, B.; Forstbauer, H.; Wischnik, A.; Scholz, C.; Fink, V.; Huober, J.; Fried, T.; Weissenbacher, T.; Härtl, K.; Kiechle, M. und Janni, W.
(2016):
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer Results from the prospective multi-center randomized Adebar trial.
In: Cancer Research, Bd. 76
Ruddy, K. J.; Rack, B.; Schwitulla, J.; Lambrechts, D.; Haeberle, L.; Schramm, A.; Trapp, E.; Scholz, C.; Beutler, A. S.; Ginsburg, E.; Couch, F.; Partridge, A. H.; Wang, L.; Weinshilboum, R. M.; Janni, W.; Vachon, C. und Fasching, P.
(2016):
Genetic predictors of chemotherapy-related amenorrhea.
In: Cancer Research, Bd. 76
Schröder, L.; Rack, B.; Sommer, H.; Koch, J. G.; Weissenbacher, T.; Janni, W.; Schneeweiss, A.; Rezai, M.; Lorenz, R.; Jäger, B.; Schramm, A.; Häberle, L.; Fasching, P. A.; Friedl, T. W. P.; Beckmann, M. W. und Scholz, C.
(2016):
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
In: Geburtshilfe und Frauenheilkunde, Bd. 76, Nr. 5: S. 542-550
Janni, W.; Harbeck, N.; Rack, B.; Augustin, D.; Jückstock, J.; Wischnik, A.; Annecke, K.; Scholz, C.; Huober, J.; Zwingers, T.; Friedl, T. W. P. und Kiechle, M.
(2016):
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
In: British Journal of Cancer, Bd. 114, Nr. 8: S. 863-871
Janni, W.; Rack, B.; Fasching, P.; Haeberle, L.; Friedl, T.; Tesch, H.; Lorenz, R.; Neugebauer, J.; Koch, J.; Jaeger, B.; Fehm, T.; Mueller, V.; Schneeweiß, A.; Lichtenegger, W.; Beckmann, M.; Scholz, C.; Pantel, K. und Trapp, E.
(2016):
Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 76
2012
Freydanck, M. K.; Laubender, Rüdiger P.; Rack, B.; Schuhmacher, L.; Jeschke, Udo und Scholz, C.
(2012):
Two-marker Combinations for Preoperative Discrimination of Benign and Malignant Ovarian Masses.
In: Anticancer Research, Bd. 32, Nr. 5: S. 2003-2008